Speakers 2018

Dr. Alexander Wittkopp
Hamm & Wittkopp
Alexander is a founding partner at Hamm&Wittkopp Patent Attorneys, based in Hamburg (Germany). He has a PhD in organic chemistry and is a German and European Patent Attorney as well as a US Patent Agent. Alexander represents his international clients in the areas of German, European, and US intellectual property law, including patent prosecution, oppositions, nullity and infringement proceedings, as well as preparing freedom-to-operate and validity opinions in the field of chemistry, chemical engineering, and pharmaceuticals. He provides complete FTO-analyses for chemical and (bio)-pharmaceutical products, conducts detailed assessments of the relevance and validity of crucial proprietary rights, and regularly represents his clients in oppositions as well as in revocation and infringement actions.
Alka Mehta
Head Formulations IP
Lupin Ltd
Dr. Alpesh Pathak
Global IP Head
Intas Pharmaceuticals Ltd.

Dr. Alpesh Pathak is currently Global IP Head at Intas Pharmaceuticals Ltd. He works on a variety of intellectual property matters at global level, including IP due diligence of Biosimilar, IP activities for 351(k) filing, FTF Para IV filing for ANDA, Handling litigation across the globe and related activities, drafting and prosecution of patent applications, drafting and negotiation of intellectual property agreements with third parties, and due diligence analyses in supporting in-licensing and out-licensing activities.

Dr. Alpesh has authored a book Entitled “Protecting Patent Fundamentals” which is appreciated and well received by the patent professionals and major universities wherein patent is one of the value added subject in the respective technical discipline.

Prior to joining Intas, Dr. Alpesh has worked with some of the leading pharmaceutical companies like Alembic Ltd, Lupin Ltd., Zydus Cadila and Cadila Pharmaceuticals. Alpesh holds a PhD from The Sardar Patel University. Besides having PG diploma in Patent Law from Nalsar Uni, Hyderabad, he has undergone various specialized courses on US litigations and European patent practices.

He also is visiting faculty at Sardar Patel University and Gujarat Technical University (GTU).

Senior manager Copyright and IP enforcement
Companies and Intellectual Property Commission, South Africa

Ms Amanda Lotheringen joined the Department of Trade and Industry (the dti) in 1993. She holds degrees from the Rand Afrikaans University in Development Economics and a Honours in Economics.

Ms Lotheringen commenced her career in the dti in 1993. In 1999 she became involved in the enforcement of the Counterfeit Goods Act, No 37 of 1997, and took responsibility for the implementation of the Act. She was responsible for the declaration of the first counterfeit goods depot and subsequently had recommended the declaration of all additional facilities that are currently operating as counterfeit goods depots.

She was also involved in the training of law enforcement officials across government departments that started to implement the Act in 2000. She attended international meetings as representative of her Government and was also nominated to be the vice chair at the first meeting of the Advisory Committee on Enforcement (ACE) held by the World Intellectual Property Organization. Last year 2015 she chaired the ACE.

Ms Lotheringen is currently the Senior Manger Copyright and IP Enforcement at CIPC. She is responsible for amongst others to coordinate and participate in “Building Respect” for IP with neighboring states, intergovernmental and non-governmental organizations and responsible for local enforcement.

Andy Camenisch
HGF Ltd.

Andy specialises primarily in patents in the fields of pharmaceuticals and chemistry on inventions relating to new chemical entities (NCEs), pharmaceutical formulations, methods of treatment, dosing regimens, medical devices, methods of manufacture, food and beverage products, materials chemistry and cosmetics products.

As well as drafting and prosecuting patent applications, Andy is also experienced in pharmaceutical patent litigation, having been involved in revocation proceedings at the UK High Court and also in the coordination of the pan-European revocation of a number of European patents covering pharmaceutical formulations and drug combinations.

Andy also manages the delivery of due diligence projects, requiring the formulation of complex prior art and FTO search strategies and advising on issues relating to patent term extensions, SPCs, regulatory data exclusivity, the enforceability of the patent portfolio (e.g. in terms of its patentability) and freedom to operate.

Andy’s client base includes International pharmaceutical companies, cosmetic companies and bulk chemical companies and UK Universities.

Andy graduated from The University of Nottingham with a first class MSc degree in Chemistry in 2006, joining the patent profession straight from University. He qualified as both a UK Chartered Patent Attorney and European Patent Attorney in 2010.

Andy J. Miller
Locke Lord LLP

Andy Miller is a Partner in Locke Lord’s IP Pharmaceutical group. His practice focuses primarily on complex litigation matters with a distinct emphasis on large-scale patent-infringement actions under the Hatch- Waxman Amendments to the Federal Food, Drug and Cosmetic Act for pharmaceutical products. He counsels clients in the areas of regulatory compliance, intellectual property, and antitrust and is well-versed in all pre-trial, trial, and post-trial phases of federal-court litigation.

Andy also has represented clients in antitrust actions related to pharmaceutical products, including actions involving reverse payments, product hopping, and REMS. During law school, he served as a research assistant for Professor Herbert Hovenkamp, a renowned expert in antitrust law.

Andy is an active participant in the Firm’s pro bono efforts through both the St. Procopius Legal Aid Clinic and Chicago Volunteer Legal Services. He currently serves on the Junior Board for CVLS.

Arshad Jamil
B.E., LL.B., PGEMP Associate Vice President & Head - Intellectual Property Rights

Arshad Jamil is a senior Indian Patent Attorney with extensive experience in the legal and IP rights fields. Arshad is the chief IP counsel and global head of IP rights at Biocon Ltd, where he is responsible for the company’s patent and trademark filings and policy, abbreviated new drug application (ANDA) filings and handling US litigation for ANDAs and Biosimilars. Arshad manages Biocon’s IP portfolio of 1100+ patents and 650+ trademarks globally.

In his previous assignment, Arshad was a senior patent attorney at Sun Pharma, where he handled ANDA litigations, including Hatch Waxman settlements. He received his Bachelor of engineering (B.E.) from Mysore University in 1991 and his Bachelor of laws(LL.B.) from Meerut University (now Chaudhary Charan Singh University) in 1998. In 2014 he completed the SP Jain Institute of Management and Research postgraduate executive management programme.

Bharati Nadkarni
Vice President
Sun Pharma

Ms Bharati Nadkarni is a pharmacist by profession with more than 17 years of work experience in IP and portfolio planning. Bharati joined Sun in 2000 in the IP team and have grown steadily at Sun, currently heading global IP litigation for Sun and also responsible for generic portfolio planning for regulated and emerging markets.

She has PhD in Pharmaceutical Chemistry and a post-graduate diploma in patent law & practice along with executive MBA.

Christopher Griffith
Green, Griffith & Borg-Breen LLP

Chris is a founding partner of Green, Griffith & Borg-Breen LLP. As a seasoned IP trial lawyer with 30+ years of experience in Hatch-Waxman law, he concentrates his practice on pharmaceuticals, chemicals and biotechnology. As a Hatch-Waxman expert, Chris leverages his advocacy and technical skills to help clients shape successful litigation outcomes. With a focus on litigation, he partners closely with his clients to provide strategic formulation development and pre-litigation counseling concerning IP and relevant FDA issues affecting 505(b)(1), 505(b)(2) and ANDA applications. He provides opinions and counseling on API and excipient selection, formulation attributes and labeling, as well as noninfringement and validity, and then works with each client to execute the desired strategy. Chris and his team are also skilled in inter partes reviews (IPRs), reexaminations, reissues and post-grant proceedings before the PTAB. He also has significant experience in navigating the 505(b)(2) pathway, including advising clients on PIV certification and Orange Book issues, related FDA issues, and patent portfolio development. Chris is also a former adjunct law professor and taught a Master's level patent law course for many years.

Craig Turner
A.A. Thornton & Co

Craig is a Partner and has a wide-ranging practice covering both contentious and non-contentious patent work in the fields of pharmaceuticals, chemistry, biotechnology, and chemical engineering. His clients include large corporations in the pharmaceuticals, biotechnology, and oil and gas industry sectors, as well as SMEs, and he has been involved for many years with Indian-based work, in particular for Cipla Ltd. Craig’s work also includes antibody technology and he is currently actively involved in litigation in this field. He has considerable experience in both EPO patent opposition and appeal work, particularly for pharmaceuticals and medical devices; and in giving freedom to operate advice. He also handles Supplementary Protection Certificates in respect of pharmaceuticals.

Craig has advised a range of clients in the life sciences field including Cipla Ltd, Neolab, Meda Pharma, Teva, Hovione International Ltd, RSR Limited, BenevolentAI, and Reckitt Benckiser.

Craig has a Natural Sciences degree and PhD from Cambridge University.

Dr. Dieter Tzschoppe
Director Operations Biotechnology / Pure and Applied organic Chemistry | Dir. 1.4
European Patent Office

Dr. Dieter Tzschoppe, of French nationality, studied chemistry at the University of Stuttgart (Germany) and holds a PhD in organic chemistry from the University of Besançon (France).

He joined the EPO in 1985 in The Hague (Netherlands) as Search Examiner in the field of pharmaceutical formulations.

After his transfer to Munich (Germany) in 1989 he worked as search and substantive examiner in the field of medical use inventions.

Since 1999 he is director of units of about 30 examiners, first in organic chemistry, since 2005 in pharmacology and since 2013 additionally in galenics and cosmetics in the cluster Pure and Applied Organic Chemistry (PAOC).

Responsible for external relations for cluster PAOC he frequently represents the cluster/EPO as speaker in company visits, conferences, workshops or in the framework of international cooperation.

In addition he is involved actively in difficult and sensitive oppositions as chairman and is responsible for the traineeship of Pan European Seal interns in DG Operations, as coordinator and instructor of the training for search tools and strategy as well as examination and opposition.

Dipak Mundra

Dipak is a Partner with LexOrbis. He is a versatile and result oriented Patent Lawyer with over 15 years of experience in handling the entire IPR (Patents) portfolio. He concentrates his practice on intellectual property litigation, strategic patent consultancy, prosecution strategy and counselling matters. He has obtained successful results for clients in numerous intellectual property cases, particularly in the field of pharmaceutical and chemical industry. Prior to LexOrbis, he was engaged for 10 years as In-house Patent Counsel for India’s largest pharmaceutical company, Sun Pharma, managing its global patent portfolio. In his illustrious career, he has not only handled numerous contentious matters in India but has actively participated in Hatch Waxman Litigation proceedings in the US District Courts and CAFC.

Geoff Hussey
A.A. Thornton & Co

Geoff Hussey is Partner and Solicitor whose practice areas are IP litigation and commercial IP. His experience includes acting for a broad range of clients in many sectors including pharmaceuticals and biotechnology (where he has natural focus as a result of his technical background), chemicals, electronics, telecoms, aviation, food & beverages and financial services.

Geoff has extensive experience in patent litigation before the UK Patents Court, Court of Appeal, and in EPO patent oppositions concerning pharmaceuticals and medical devices including the coordination of parallel proceedings across many jurisdictions in Europe and the US. Geoff’s contentious IP experience also covers design rights as well as trade marks, passing off, copyright, and breach of contract disputes involving IP.

Geoff has advised many life sciences clients including Gilead, Cipla Ltd, Bial – Portela, Dr Reddy’s, Pfizer, ConvaTec and Coopervision.

Some of Geoff’s notable life sciences cases include:
  • Napp Pharmaceuticals v Dr Reddy’s & Sandoz (buprenorphine patch patent infringement)
  • Smith & Nephew v ConvaTec (gel-forming silverised wound dressing patent validity, infringement and EPO opposition)
  • GE Healthcare v PerkinElmer (scintillation proximity assay patent revocation and entitlement) 
Geoff has a degree in Genetics from the University of Nottingham.
James T. Peterka
Locke Lord LLP

Jim Peterka is a member of Locke Lord's IP Pharmaceutical and Biotechnology and IP Litigation groups, and focuses his practice primarily on Hatch-Waxman pharmaceutical patent litigation. Jim regularly counsels generic pharmaceutical and biotechnology companies in connection with patent issues and in all aspects of patent litigation. His Hatch-Waxman experience ranges from pre-litigation activities, including patent designaround and invalidity counseling and preparation of Paragraph IV notice letters, through discovery, claim construction proceedings, trial, and appeal. He also represents clients in connection with a variety of FDA regulatory issues.

In addition to his Hatch-Waxman practice, Jim has significant experience involving patent litigation and patent counseling in a variety of other areas, including food science, materials science, and mechanical engineering. His intellectual property practice also extends to trade-secret litigation, copyright and trademark prosecution and litigation, and evaluation and analysis of intellectual property in the context of commercial transactions.

Kirit Palsana
Director, Software Development

Kirit is Director at Knovos (Previously known as Capital Novus) India. Kirit is a graduate from the prestigious NIT, Surat & Masters in Automation Programming from University of Pune. He is instrumental in setting up Knovos’ India operations from the scratch to developing global support system from India. He has over decade of experience in Designing innovative technology solution for eDiscovery & Information Governance. He has also successfully handled and assisted major Indian Generic Pharmaceuticals in their Hatch-Waxman Patent Litigations. He was pivotal in expanding Knovos operations in Tokyo, Paris and Germany. He was a special invitee by Gov. of Bhutan for providing solutions on Strategic Governance. He also played a key role making Knovos a Technology Partner for the Government of Uttarakhand, and assisted Hon’ble Chief Minister of Uttarakhand Shri Trivendra Singh Rawat to launch the CM Monitoring Dashboard - UTKARSH (Uttarakhand – Achieving Results in Systematic and Holistic way). UTKARSH is the only CM Dashboard in the country powered by Knovos’ Cascade – An Outcome based Budgeting & Performance Monitoring System. He played a key role in establishing strategic partnership in the Middle East region. He is also regularly invited for expert talk by various professional forums and universities.

Komal Kalha
Senior Counsel
US Patent and Trademark Office

Komal Kalha, senior counsel, is a policy and legal advisor on all aspects of intellectual property (IP) for India and other South Asian countries. She serves as the lead IP specialist for India. Ms. Kalha promotes high standards of IP protection and enforcement, as well as cooperation between the United States and South Asian governments on IP matters.

Ms. Kalha started her career at Amarchand Mangaldas, one of India’s leading law firms. In addition to her attorney experience, she has designed and taught courses on IP law and related subjects at various universities in India and has advised Indian states on IP policy matters.

Ms. Kalha holds a BSc and LLB (Hons) from the National University of Juridical Sciences, Calcutta, India, and an LLM in IP from the George Washington Law School, Washington D.C.

Martyn Fish
HGF Ltd.

Martyn advises clients on all aspects of contentious and non-contentious intellectual property law with a focus on intellectual property litigation.

He has been involved in numerous High Court actions in the fields of patents, trade marks, copyright, design rights and misuse of confidential information. He regularly acts for clients at all stages of litigation from pre-action issues right through to trial and appeal.

Martyn’s work often has an international aspect and he has considerable experience of coordinating legal teams in various jurisdictions.

Martyn’s clients are drawn from all sectors and include multinational companies, Universities and SMEs. He has been successful in a number of high profile patent infringement actions with technologies as diverse as pharmaceuticals (Glenmark Generics v GSK [2013] EWHC 148 (Pat) concerning GSK’s anti-malarial, Malarone), medical devices and complicated hydraulic devices (such as Triumph Actuation Systems Inc v Eaton Limited [2007] EWHC 1367 (Pat))

Martyn has extensive experience of the Intellectual Property Enterprise Court and in 2013 successfully acted for the defendants in the first trial before the new court (Manvers Engineering v Lubetech). He also has experience of entitlement, revocation and ownership disputes before the UK Intellectual Property Office.

Mythili Venkatesh
Managing Associate
S. Majumdar & Co.

Ms. Mythili Venkatesh is a Post-Graduate (Organic Chemistry) and is a Registered Indian Patent Agent and Registered Indian Trademark Agent. Prior to joining practice, she had worked in the field of synthetic chemistry of dyes, pigments and bulk drug research and development having being associated with companies like Mazda Ltd, Cipla Ltd and Nicolas Piramal Ltd.

Having been in the practice for over 12 years, her specialties include patent mapping and landscaping, patent drafting, patentability, invalidity, FTO and non-infringement opinions and various other technical aspects associated with patenting. She has successfully handled several patent prosecution proceedings before the Patent Office in inventions related to APIs & chemical intermediates, Patent oppositions relating to APIs & Pharmaceutical compositions. She is actively involved in proceedings before the Intellectual Property Appellate Board (IPAB). She has been a part of several IP awareness programs across the country.

Nichole Valeyko
Lerner David

Nichole Valeyko represents pharma and biotech clients in trials before the USPTO's Patent Trial and Appeal Board (PTAB), counsels them in complex ANDA and 505(b)(2) matters, and assists them in developing strong patent portfolios. Her diverse experience provides her with valuable insights to assist clients in achieving their business and intellectual property goals. She has helped clients obtain hundreds of U.S. and international patents and successfully assisted clients on case-dispositive litigation issues. Her keen knowledge of patent prosecution proves invaluable to her post-grant practice, where Nichole has successfully represented a number of generic applicants challenging patents before the PTAB. Nichole relies upon her experiences in both patent litigation and procurement to help guide clients in obtaining valuable and meaningful patent protection. Nichole’s services include patent prosecution, enforcement, IP due diligence, partnering agreements, freedom-to-operate assessments, and patent opinions, as well as counseling on portfolio strategy, and IP issues for start-ups. Her work spans a variety of technical areas including chemical, pharmaceutical, food science, medical device, and biotechnology. Nichole obtained her Masters in Biotechnology from Johns Hopkins University, where she focused her studies on both the scientific and business development aspects of biotechnology. She has been recognized recently as a Rising Star in Intellectual Property by New Jersey Super Lawyers Magazine.

OP Gupta (IAS)
Controller General of Patents, Designs & Trade Marks, DiPP
Ministry of Commerce and Industry, Government of India
Dr. Paras R Vasanani
Assistant General Manager – Global Intellectual Property Department
Amneal Pharmaceuticals Pvt Ltd.

Dr. Paras Vasanani is presently associated with Amneal Pharmaceuticals Pvt Ltd as an Assistant General Manager of Global IP Department. He has started his career as IP professional from Alembic Pharma then Zydus Pharma and presently in Amneal Pharma with vast experience in the area of Intellectual Property Management with specific focus on IP due diligence for ANDAs and 505b2, Invalidation and litigation aspects, companies product portfolio management by identifying new product opportunities ANDA & 505b2, execution of 505b2 products etc. He has attended many litigations at US district court & CAFC in person. In the field of IP he has worked for various countries like USA, India, Europe, Canada, Mexico, Brazil and Australia.

Dr. Paras has pursued M.Pharm and Ph.D in NDDS from M.S.University, Vadodara. He is registered Indian Patent Agent and Trademark Agent. He has spoken at various National & International Conferences, Symposiums and Universities on IP matters. Currently he is perusing MBA from Indian Institute of Management-Ahmedabad (IIMA).

Paul A Braier
Greenblum & Bernstein, P.L.C., USA

Paul is a shareholder at G&B, and a member of the Pharmaceutical; Biotechnology; Litigation and Trial; and Client Counseling practice groups of Greenblum & Bernstein. His work in these groups includes preparing and supervising preparation of infringement and validity opinions, Notice Letters, litigation, and FDA citizen petitions, as well as general counseling, particularly in the pharmaceutical, chemical, and medical arts. Paul is involved extensively in the firm's pharmaceutical practice, and advises drug companies (primarily generics) on strategic planning and new product introduction. He works extensively with Hatch-Waxman issues and the interface of patent and FDA law.

Dr. Poonam Raghuvanshi
Vice-President & Head, Intellectual Property
Dr. Reddy’s

Dr. Poonam Raghuvanshi, M.Pharm Ph.D is the Vice-President & Head, Intellectual Property, Dr. Reddy’s. She has more than 25 years of Industrial experience in Pharma Research and Intellectual Property.

Ranjna Mehta Dutt
Asian Patent Attorneys Association (APAA).

Enrolled with Bar in 1992, Ranjna is a prominent face of the Indian IP fraternity and leads the Life Sciences practice of the Firm. She has extensive experience in rendering patentability opinions, carrying out and analysing patent searches including freedom to operate searches, drafting patent specifications, filing national and international (PCT) applications, handling patent applications in diverse fields of technology, conducting patent oppositions and handling issues of enforcement. She is well versed in the intricacies of patent law and skilled at formulating strategy for developing and managing patent portfolios. Her experience is particularly pronounced in pharmaceutical, biotech and chemical patents, with a special focus on appeals and contentious matters. She has handled many high profile matters before various forums including the Indian Patent Office and the Intellectual Property Appellate Board (IPAB).

That apart, Ranjna also has significant expertise in filing and prosecuting design applications as well as handling the cancellation of designs. Her experience also extends to the protection of plant varieties and obtaining necessary approvals from the National Biodiversity Authority.

She participates in various IP initiatives – often delivering lectures on IP law at domestic and international fora; adjudging moot court competitions at universities; and assisting the government on policy development and related issues. She has also written several pieces for renowned IP publications and comments frequently on topical developments.

Currently, she holds the position of Vice-President, Asian Patent Attorneys Association (APAA). She is also a member of the APAA International Designs Committee. She been voted as a leading IPR attorney in India in a number of IP surveys conducted by renowned IP publications.

Ravi Srinivasan
Patent Attorney, J A Kemp

Ravi has over 20 years of professional experience. He is known for his practical and commercial approach to patent work. He handles cases in both organic and inorganic chemistry, with particular expertise in the pharmaceutical field where he advises startup companies as well as medium-sized and large pharmaceutical companies.

In the pharmaceutical field, Ravi has acted in many high-profile conflicts, on drugs including doxorubicin, epirubicin, docetaxel, aclidinium, ebastine, plerixfor, betrixaben, aztreonam, heparin, risperidone and sofosbuvir. He has an impressive track record in defending patent estates protecting innovative pharmaceutical products. However, he is equally at home advising on freedom to operate and due diligence matters and drafting, filing and prosecuting patent applications at the European Patent Office (EPO) and elsewhere. Many of Ravi's clients have broad filing programmes, and Ravi routinely takes responsibility for filing pharmaceutical applications in over 40 countries.

In addition to his experience at the European Patent Office, Ravi is qualified as a litigator and holds the Higher Courts Litigation Certificate, which enables him to conduct IP litigation in the Intellectual Property Enterprise Court and the High Court and on appeal to the Court of Appeal and the Supreme Court.

Ravi is an overseas citizen of India, and is a frequent visitor to the country. He has specialist expertise in prosecuting Indian patent applications, and has experience of speaking at an opposition hearing at the Indian Patent Office.

Richa Pandey
Patent Attorney & Partner
Krishna and Saurastri Associates

Ms. Richa Pandey is a Partner, Advocate and Patent Attorney at Krishna and Saurastri Associates LLP, Delhi (Gurgaon) Office. Her core practice areas include patent filing, patent prosecution, patent opposition, patent litigation, patentability opinions, searches, invalidity opinions and portfolio management. Ms. Pandey has also been a guest speaker at various national & International conferences on Intellectual Property. Ms. Pandey holds a Degree in Law and a Bachelor’s Degree in Science from the University of Lucknow. She is registered to practice before the Intellectual Property Office India and is also registered with the Bar Council of India.

Ron Daignault
Goldberg Segalla

Ron Daignault, a partner at Goldberg Segalla, is an intellectual property litigator and trial attorney with a focus on pharmaceutical patents. As a Hatch-Waxman litigator with over 25 years of experience covering both generic and branded pharmaceuticals, Ron has guided clients through litigation involving dozens of patents, products, formulations and designs, and methods of use. Ron has been involved in numerous bench and jury trials and evidentiary hearings, serving as lead counsel or second chair in most of them, and has also argued before several U.S. Courts of Appeals and the New York State Appellate Division.

A frequent writer and speaker on topics in the field of intellectual property, Ron has held a spot on the New York Metro Super Lawyers list consistently since 2012, and Managing Intellectual Property has recognized him as a “Star” in both Life Sciences and Intellectual Property every year since 2013. He currently serves as an Advisory Board member of Bloomberg/BNA's Life Sciences Law and Industry Report and an Amicus Committee member of the New York Intellectual Property Law Association. Outside of practicing law, Ron is an amateur cook, a civic leader in his Brooklyn, NY neighborhood, and a passionate athlete — he has finished 15 marathons (including four Boston Marathons) and the New York City Ironman.

Sailesh K. Patel
Schiff Hardin LLP

As co-leader of Schiff Hardin’s Intellectual Property Group, Sailesh K. Patel also co-chairs the firm’s Pharmaceuticals and Biologics Patent Litigation Team and is a seasoned trial attorney. He is passionate about implementing creative and scientifically sound arguments for his clients, which has resulted in legal precedent-setting cases.

Sailesh has served as lead counsel on numerous patent infringement litigation matters, particularly complex Hatch-Waxman matters. He has also served as an adjunct professor of pharmaceutical patent law at the Chicago-Kent School of Law. With a background in chemical and biomedical engineering, he is familiar with the language of the pharmaceutical industry. He also assists companies in Paragraph IV and biosimilars design strategies, helping his clients protect their scientific discoveries.

He received a B.S. in Chemical Engineering from Northwestern University and his J.D. from Boston College Law School.

Sanjay Kumar
Former Head - Legal, Ethics and Compliance
GSKConsumer ( JV of GSK & Novartis)

Sanjay is a Visionary, strategist & planner with multi-cultural experience in spearheading the entire Legal, Ethics & Compliance functions with hands-on expertise in Legal Operations, Compliance, corporate affairs, Privacy& Data protection, Digital business & Cyber Security and Legal disputes with focus on accomplishing organizational goals and objectives.

Starting his carier with Bhasin & Co LLP Associate, he has worked tierlessly in pharma sector offering efficient management advisory and effective management of Legal Operations & Global Ethics & Compliance.

He was Head – Legal, Piramal LifeSciences, General Counsel of Hetero Group before joining GSK Consumer. He has completed LLB and LLM from University of Delhi and has an international exposure and led several studies and letigations in countries like Germany, Brussels, Spain, Swiss apart from USA & UK.

Saya Choudhary Kapur
Singh & Singh LLP

She is a graduate from Delhi University with a B.Sc (Hons) degree in Physics. She completed her law from Delhi University and graduated in 2007. She has also done post graduate diploma courses in IPR law and Securities and Banking Laws. Before joining Singh & Singh in May, 2008, she used to work for a Delhi based Corporate Law Firm. She heads the patent litigation team which primarily deals with the patent litigation pertaining to multiple fields including telecommunications and pharmaceuticals. She has been working with firm for past 10 years and has handled various landmark cases which include amongst others Novartis vs Union of India, Merck vs Glenmark etc.

She has extensive experience in relation to disputes pertaining to the field of Standard Essential Patents. She has been handling SEP cases since 2009. She was in-fact involved in the first SEP case in India, pertaining to the field of DVD technology, filed by Philips against an Indian party. She has also handled the highly contentious dispute between Vringo and ZTE. Currently, she is handling all Ericsson’s and Dolby’s infringement suits filed against various Indian and Chinese mobile phone players. She actively advises clients in relation to various issues pertaining to procurement, licensing and enforcement of Standard Essential Patents. She has also experience of negotiating and executing FRAND licensing deal on behalf of SEP owners. She has also handled various mediation and arbitration proceedings in relation to FRAND licensing issues.

In 2015, she has been nominated for the award of IP Rising Star by International Financial Law Review. IN 2017, she has been recognized as one of the leading patent professionals in India by IAM Magazine. She has been a regular Speaker at various international and national Seminars and workshops which include amongst others MIP International Patent Forum, London.

She is the founding member of Indo German Association for Legal Cooperation.

Seema Singh
Associate Director
Scott B. Feder
Locke Lord LLP

Scott Feder concentrates his practice in the commercial litigation area, particularly in patent infringement and other intellectual property matters. For the past 30 years, he has represented clients in the pharmaceutical and biotechnology areas on a variety of issues, including patent, trademark, trade secret, slander and other commercial litigation matters. He has been involved in litigation matters encompassing a variety of drug products, chemical processes, and recombinant DNA technology, with extensive background in pharmaceutical sciences, biochemistry and biotechnology.

Scott has litigated several intellectual property infringement actions, including Hatch-Waxman actions, in the United States District Courts, and has argued several cases before the United States Court of Appeals for the Federal Circuit. He was trial counsel in Senju Pharmaceutical Co. Ltd. v. Apotex Inc., 717 F. Supp. 2d 404 (D. Del 2010) (Zymar® patent held invalid for obviousness). He was also trial counsel in Acorda Therapeutics Inc. v. Apotex Inc., WL 4074116 (D.N.J. 2011) (Zanaflex patent held invalid for lack of enablement and not infringed) and in SmithKline Beecham Corp. v. Apotex Corp., 272 F. Supp. 2d 772 (N.D. Ill. 2003, Posner, J.)(Paxil® patent not infringed), aff'd on other grounds, 365 F.3d 1306, 1308 (Fed. Cir. 2004) (patent invalid for violating public use bar), vacated on reh'g en banc, and aff'd on other grounds, 403 F.3d 1331 (Fed. Cir. 2005)(patent invalid for inherent anticipation). Mr. Feder presented oral argument for the appellant in Torpharm, Inc. v. Ranbaxy Pharms., Inc., 336 F.3d 1322 (Fed. Cir. 2003), in which the United States Court of Appeals vacated a summary judgment ruling that invalidated a patented process for making a generic version of the drug Zantac®. He also presented oral arguments in Ranbaxy Pharms., Inc. v. Apotex Inc., 350 F.3d 1235 (Fed. Cir. 2003) and Abbott Laboratories v. Torpharm, Inc., 300 F.3d 1367 (Fed. Cir. 2002).

Shashank Upadhye
Amin Talati Upadhye

Shashank Upadhye is a partner at Amin Talati Upadhye, LLP. For 20+ years, he has focused on pharmaceutical law, with an emphasis on IP and FDA issues. He also spent many years as the chief of legal/IP/FDA counsel at Apotex, Sandoz, and Eon Labs, so he brings key business savvy to help clients. He is a prolific speaker and recognized leader in the Hatch Waxman/Para. IV field. He counsels both brand companies [505(b)(2) applicants] seeking to strategically patent and launch their brand name products in the long term; and to generic companies seeking to challenge patents (opinions and litigation), maximize 180-day exclusivity, and with FDA compliance (483’s, Warning Letters, and enforcement). He’s been involved in some of the biggest product launches and his strategic IP & FDA thinking has helped shape the law and drive client business. He provides input at every stage of the product lifecycle from product selection, R&D, regulatory affairs, product launch, and ongoing marketing/sales. Shashank is also the author of the key legal text on pharmaceutical and FDA law and other articles. Many of his publications can be accessed through his bio on the firm’s website. He can be reached at: shashank@amintalati.com and his bio is here:

Srikanta Patra
Pellets Pharma
Head, Global IP & Strategic Planning

Mr Srikanta Patra with a deep industrial experience currently leads Intellectual Property Rights, Product portfolio and Strategic Planning at Pellets Pharma Limited.

He is an Indian Patent Agent and an accomplished IP strategist, inventor, innovation consultant and product portfolio specialist. He holds MS Pharm in Pharmaceutics from National Institute of Pharmaceutical Education and Research (NIPER) and a gold medallist in his graduation.

His areas of expertise include Intellectual Property Rights, Product Portfolio Management and Innovation Consultation. Prior to joining Pellets Pharma Limited, he was associated with Aizant Drug Research as Head of IP & Product portfolio management and was instrumental in identification and filing of several NCE-1 & Paragraph IV ANDA filling as well various 505 b (2) research. He also worked in Pharma Majors like Lupin and Cadila Healthcare. Mr. Patra is a registered Patent Facilitator at Indian Patent Office to help individual scientist and start-up.

Stephen R Auten
Taft Stettinius & Hollister LLP

STEVE AUTEN is head of Taft's Pharmaceutical & Life Sciences Litigation practice area. He is a widely recognized and seasoned attorney in Hatch-Waxmanand biosimilar matters,including related patent litigation, and is followed by key industry leaders(brand and generic alike), law firms, analysts, educators and others on his LinkedIn blog "Hatch Waxman ANDAL itigation Forum" or HALF, which has over 8,000 members worldwide. He currently represents clients primarily in the areas of Paragraph IV design strategies, Hatch-Waxman litigation, and biosimilar market opportunities. Prior to Taft, he lead the IP division for Sandoz for several years.

In addition to litigating Paragraph IV cases, Steve has served as a co-editorand chapter author on several leading treatises for pharmaceutical litigation, as well as contributed to a forthcoming book on evidence in Hatch-Waxman cases.

Steve is recognized by Chambers USA as a top Intellectual Property attorney in Illinois,as well as by hispeers in The Best Lawyers in America for IP Litigation, as an Illinois Leading Lawyer, an Illinois Super Lawyer in IP Litigation, and as a "World's Leading Patent Practitioner" by Intellectual Asset Management magazine.

Steve Coyle
Cantor Colburn LLP

Steve Coyle is a partner and co-chairs the firm's Litigation Department. He is a trial lawyer with more than 20 years' experience in litigating and trying complex disputed matters, and he has specialized in patent and all varieties of intellectual property litigation for the past 15 years. Steve’s areas of focus include ANDA and Hatch-Waxman litigation, where he has represented the rights of generic drug manufacturers and helped them to bring products to market. He is also the Group Leader of Cantor Colburn’s Pharmaceutical Litigation Practice. Steve represents clients as both plaintiffs and defendants in a variety of other patent matters, involving such diverse technologies as software, cybersecurity, fiber optics, induction lighting, microwave circuit boards, robotic measurement equipment, media packaging, flexible gas piping, and telecommunications. Steve has substantial experience litigating trademark, copyright, and trade secret matters as well. He has tried and litigated patent and other intellectual property cases throughout the country, and he has represented clients in alternative dispute resolution forums such as arbitrations and mediations. Steve has also handled multiple appeals, including before the Federal Circuit. In all of his cases, Steve strives to develop and follow a pragmatic strategy that advances not only his clients’ short term litigation goals but also their long term business needs. Steve has tried cases in state and federal courts since 1994. In addition to patent litigation, Steve has litigated trademark and trade dress cases, trade secret cases, copyright cases, non-compete disputes, licensing matters, and complex commercial disputes. He has handled cases in numerous courts throughout the country and has argued before the First and Federal Circuit Courts of Appeals.

Swati Veera
Senior In-House Patent Attorney
Indoco Remedies Limited

Swati Veera is Senior In-House Patent Attorney at Indoco Remedies Limited. Ms. Veera has over 23 Years of experience in the field of IP, particularly Patents. Her experience includes conducting invalidity and non-infringement studies and rendering opinions; devising Hatch-Waxman litigation strategy and related issues, patent drafting, prosecution, patent portfolio management, patentability evaluation, and devising overall pharmaceutical patent strategies and implementing the same.

In her current role as Senior In-House Patent Counsel at Indoco Remedies Limited, Ms. Veera provides strategic expertise on a broad range of IP issues, advises senior management on IP issues that have legal implications, prepares legal opinions. Prior to joining Indoco, Ms. Veera worked as In-House Patent Counsel & Head of Patents Dept. at Piramal Healthcare Ltd. She has also worked as patent professional for leading Indian Pharmaceuticals including Sun Pharma. and Lupin.

Recently, Ms. Veera is recognised amongst “Top 100 Powerful Women in Law” by World Intellectual Property Forum. She has also been actively involved in spreading patent awareness among different functions of the Company through the designing and lecturing of In-house Patent training courses. She is a frequent speaker in IP programs organised in India.

Taranpreet Singh Lamba
Vice President of Intellectual Property and Product Portfolio Management
Glenmark Pharmaceuticals Limited

Mr. Taranpreet Singh Lamba is presently working as Vice President of Intellectual Property and Product Portfolio Management in Glenmark Pharmaceuticals Limited, Mumbai. He has more than 17 years of rich experience in the patent with specific focus in patentability aspect of Innovations, managing patent portfolios, life cycle management infringement matters and oppositions for various countries including India, Russia, Brazil, Mexico, Europe and US in the field of NCE, generics and biotechnology. He has handled various complex litigations and has done out of court settlements in various jurisdictions. Also responsible for making Product Portfolio for Glenmark Globally.

Taranpreet Singh Lamba has written articles on important intellectual property issues and has spoken at various National and International conferences on IP matters. He is a pharmacy graduate and has done M. Tech in Pharmaceutical Technology from NIPER and has further also done specialization in patent law.

Tedd Van Buskirk
Lerner David

Tedd Van Buskirk, a partner with Lerner David, is a business-minded and result-driven intellectual property litigator with a life sciences focus, serving clients in the pharmaceutical, medical device, and biotechnology industries. Over the course of his 20+ year career, Tedd has earned a reputation for his ability to absorb the scientific, legal, and business implications and nuances of virtually any technology and—more importantly—for his knack in making them understandable to nontechnical audiences, especially in the courtroom. He has a track record of success helping clients navigate the complex intersection of the patent and FDA laws relating to the Hatch-Waxman Amendments. From the earliest blockbusters to the multi-defendant FTF cases of today, Tedd has litigated ANDA cases and prosecuted parallel inter partes review (IPR) proceedings from filing through trial and appeal from A to Z (ALOXI®, ANDROGEL®, CLARITIN®, EFFIENT®, INVOKANA®/INVOKAMET®, LIDODERM®, NEURONTIN®, OXYCONTIN®, PREVACID®, PRECEDEX®, PRILOSEC®, TRINTELLIX®, ZANTAC®, and ZOFRAN®, among others). In addition to his litigation practice, Tedd is a registered patent attorney who prepares and prosecutes patent and trademark applications and has handled patent interferences, post grant proceedings, and trademark oppositions. Prior to joining Lerner David, Tedd was a partner in several AmLaw 100 firms. He is a frequent panelist and speaker on Hatch-Waxman matters and is often quoted in the press and published on issues affecting the pharmaceutical industry.

Vidya Subramanian
Deputy General Manager- IPR
Reliance Life Sciences

Vidya Subramanian is associated with the field of Intellectual Property in India for the last 15 years. She has done her M.Pharm from ICT (formerly UDCT) and also a registered Indian Patent Agent.

She has worked with Pharmaceutical industries like J. B. Chemicals and Aurobindo Pharma before joining Reliance Life Sciences.

Currently, Vidya is associated with Reliance Life Sciences, as Deputy General Manager- IPR At Reliance, she has been involved in patent protection of diverse domains of Life Sciences and also engaged in providing FTO reports and patent landscapes.

Yoshiyuki OSABE
Deputy Director
Patent Information Policy Planning Division, Japan Patent Office.

Yoshiyuki OSABE graduated from the University of Tokyo, Faculty of pharmaceutical science, and Graduate School in University of Tokyo (Master).

With majors in Intellectual Property and Biotechnology he joined the Japan Patent Office as a Patent Examiner in 2002.

Yoshiyuki is a visiting scientist in Catholic University of Leuven, Belgium, the Deputy Director in Bio-industry division, METI, Economist/ IP analyst in OECD and Administrative Judge in JPO.

He has authored, “Towards More Inclusive IP Analysis by Frontier Tools”, Intellectual Property Rights, which is edited by Sakthivel Lakshmana Prabu and Timmadonu Narasimman Kuppusami Suriyaprakasha.

His other authored works include Innovation Front and Technology Linkage, Business and Management Studies, 2016, Vol.2, No.1, pp 88-94 and Future Information Technology, Springer, Lecture Notes in Electrical Engineering Volume 309, 2014, pp 549-554